These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1990781)

  • 1. Role of new antiplatelet agents as adjunctive therapies in thrombolysis.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Am J Cardiol; 1991 Jan; 67(3):12A-18A. PubMed ID: 1990781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Mol Biol Med; 1991 Apr; 8(2):235-43. PubMed ID: 1806765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ; Prager NA; Sobel BE; Abendschein DR
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
    Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
    J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
    Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
    Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
    Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.
    Yao SK; McNatt J; Anderson HV; Eidt J; Cui KX; Golino P; Glas-Greenwalt P; Maraganore J; Buja LM; Willerson JT
    Am J Physiol; 1992 Feb; 262(2 Pt 2):H374-9. PubMed ID: 1539695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    Saito T; Saitoh S; Asakura T; Kanke M; Owada K; Maruyama Y
    Int J Cardiol; 1993 Mar; 38(3):225-33. PubMed ID: 8463004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
    White HD; French JK; Hamer AW; Brown MA; Williams BF; Ormiston JA; Cross DB
    J Am Coll Cardiol; 1995 Jan; 25(1):218-23. PubMed ID: 7798505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reocclusion: the flip side of coronary thrombolysis.
    Verheugt FW; Meijer A; Lagrand WK; Van Eenige MJ
    J Am Coll Cardiol; 1996 Mar; 27(4):766-73. PubMed ID: 8613601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic, antiplatelet, and antithrombotic agents.
    Grines CL
    Am J Cardiol; 1992 Dec; 70(21):18I-26I. PubMed ID: 1471601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
    Haskel EJ; Adams SP; Feigen LP; Saffitz JE; Gorczynski RJ; Sobel BE; Abendschein DR
    Circulation; 1989 Dec; 80(6):1775-82. PubMed ID: 2513145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. After coronary thrombolysis and reperfusion, what next?
    Bang NU; Wilhelm OG; Clayman MD
    J Am Coll Cardiol; 1989 Oct; 14(4):837-49. PubMed ID: 2677087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolytic therapy for myocardial ischemia and infarction.
    Rapaport E
    Ann Epidemiol; 1992 Jul; 2(4):543-8. PubMed ID: 1342305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
    Malcolm AD; Keltai M; Walsh MJ
    Eur Heart J; 1996 Oct; 17(10):1522-31. PubMed ID: 8909909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K; Hornberger W
    Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.